Alterity Therapeutics Stock (NASDAQ:ATHE)
Previous Close
$1.14
52W Range
$1.01 - $5.41
50D Avg
$1.28
200D Avg
$1.73
Market Cap
$10.47M
Avg Vol (3M)
$11.54K
Beta
0.68
Div Yield
-
ATHE Company Profile
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
ATHE Performance
Peer Comparison
| Ticker | Company |
|---|---|
| PMVP | PMV Pharmaceuticals, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| ADIL | Adial Pharmaceuticals, Inc. |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| ADTX | Aditxt, Inc. |
| ARTL | Artelo Biosciences, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| SRZN | Surrozen, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| VCNX | Vaccinex, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| HCWB | HCW Biologics Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| TARA | Protara Therapeutics, Inc. |
| ATXI | Avenue Therapeutics, Inc. |
| ABIO | ARCA biopharma, Inc. |
| ELYM | Eliem Therapeutics, Inc. |